Recruiting

Prednisone with Pain Meds

Sponsor:

Mayo Clinic

Code:

NCT07223580

Conditions

Ureteroscopy

Post Operative Pain

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Corticosteroid

Placebo

Study Details

Brief summary:

The purpose of this research is to evaluate if corticosteroid (prednisone) after ureteroscopy and placement of the stent will help alleviate postoperative pain control in addition to other normal postoperative pain medications

Conditions

Ureteroscopy

Post Operative Pain

Study ID

NCT07223580

Start date

Jan 23, 2026

Status verified date

Jan, 2026

Completion date

Dec 1, 2027

Anticipated

Primary completion date

Jan 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients who are diagnosed with kidney or ureteral stones confirmed on imaging (CT of the abdomen or pelvis) and who elect for definitive treatment via ureteroscopy with placement of ureteral stent.
  • Age 18 years or older
  • Patients of either gender
  • Patients of all ethnic backgrounds
  • Cable of giving informed consent
  • Capable and willing to fulfill the requirements of the study.

Exclusion Criteria:

  • History of chronic pain
  • Chronic use of opioids or other pain medication (>12 weeks)
  • Known allergies to corticosteroids.
  • Known or suspected pregnancy
  • Inability to give informed consent or unable to meet requirements of the study for any reason.
  • Bilateral ureteroscopy
  • Current Corticosteroid Use
  • Diabetic patients who are insulin dependent

Study Design

Enrollment

90 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Standard of care plus Corticosteroid

Participants will receive standard of care postoperative ureteroscopy medication, with the addition of prednisone 25 mg.

placebo comparator: Standard of Care

Participants will receive standard of care postoperative ureteroscopy medication, with the addition of a placebo pill.

Interventions

Corticosteroid

In addition to the standard of care postoperative ureteroscopy medication, participants will be given prednisone 25 mg orally, once a day for 5 days post-surgery.

Placebo

In addition to the standard of care postoperative ureteroscopy medication, participants will be given a placebo pill orally, once a day for 5 days post-surgery.

Primary outcome measure

  • Change in Visual Analog Scale Pain Score [ Time Frame: Baseline, Day 1 (Post-operatively), Day 2, Day 3 ]

Central Contacts and Locations

Central contacts

Rev V. Vilasan Shylaja

480-574-1466

Locations

Mayo Clinic in Arizona

Recruiting

Scottsdale, Arizona, United States, 85259

Contacts

Rev V. Vilasan Shylaja

480-574-1466

Principal Investigator:

Karen L. Stern, MD

More Information

Sponsor

Mayo Clinic

Last update posted

Feb 3, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-02-03.